Company intelligence / Profile preview

Pronova Biocare

Lysaker, Norway

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Pronova BioPharma is a Norwegian pharmaceutical company specializing in the development and manufacture of marine-derived omega-3 fatty acids. The company is most notable for creating Omacor (marketed as Lovaza in the US), the first FDA-approved prescription omega-3 drug for treating severe hypertriglyceridemia. Utilizing advanced purification technologies, Pronova produces high-concentration active pharmaceutical ingredients from fish oils. In 2013, the company was acquired by BASF to strengthen its position in the global omega-3 market. Today, it operates as a subsidiary within BASF's Nutrition & Health division, maintaining its manufacturing and R&D presence in Norway.

Therapeutic areas: Metabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

GSKTakedaAstraZeneca

Beyond the preview

Go deeper on Pronova Biocare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pronova Biocare.

Explore the full profile